摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

D-蛋氨酸甲酯盐酸盐 | 69630-60-0

中文名称
D-蛋氨酸甲酯盐酸盐
中文别名
D-甲硫氨酸甲酯盐酸盐;2,6-二氯嘌呤核苷;2-氨基-4-(甲硫基)丁酸甲酯盐酸盐
英文名称
methyl D-methioninate hydrochloride
英文别名
D-methionine methyl ester hydrochloride;methionine methyl ester hydrochloride
D-蛋氨酸甲酯盐酸盐化学式
CAS
69630-60-0
化学式
C6H13NO2S*ClH
mdl
——
分子量
199.702
InChiKey
MEVUPUNLVKELNV-NUBCRITNSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    149-150 °C
  • 溶解度:
    溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

  • 辛醇/水分配系数(LogP):
    0.66
  • 重原子数:
    11
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    79.2
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    存储温度应保持在0°C。

SDS

SDS:c300d45f39668597a201d7a068157be2
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: H-D-Met-OMe HCl
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: H-D-Met-OMe HCl
CAS number: 69630-60-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H13NO2S.ClH
Molecular weight: 199.7

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

HDMet-OMe公司生产的HCl是蛋氨酸(HY-13694)的衍生物。

反应信息

  • 作为反应物:
    描述:
    D-蛋氨酸甲酯盐酸盐 在 palladium on activated charcoal benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 氢气三乙胺 作用下, 以 四氢呋喃甲醇二氯甲烷 为溶剂, 生成 methyl (2R)-2-[[(1R,3S)-1-(4-hydroxy-3,5-dimethoxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl]amino]-4-methylsulfanylbutanoate
    参考文献:
    名称:
    The synthesis of amino-acid functionalized β-Carbolines as topoisomerase II inhibitors
    摘要:
    The synthesis and biological activity of amino acid functionalized beta -carboline derivatives, which are structurally related to azatoxin and the tryprostatins, are reported. These compounds were assayed for their growth inhibition properties in H520 and PC3 cell lines and were examined for their abilities to inhibit topoisomerase II-mediated DNA relaxation. (C) 2001 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(01)00136-6
  • 作为产物:
    描述:
    甲醇D-蛋氨酸乙酰氯 作用下, 以86%的产率得到D-蛋氨酸甲酯盐酸盐
    参考文献:
    名称:
    石胆酸的氨基酸缀合物作为 EphA2 受体的拮抗剂
    摘要:
    Eph 受体-ephrin 系统是开发新型抗血管生成药物的新兴目标。我们最近发现石胆酸 (LCA) 是一种能够阻断癌细胞中依赖 EphA2 信号的小分子,这表明其 (5β)-cholan-24-oic 酸支架可用作模板来设计新一代改进的EphA2 拮抗剂。在这里,我们报告了通过将其羧基与不同的 α-氨基酸共轭而获得的一组扩展 LCA 衍生物的设计和合成。构效关系表明亲脂性氨基酸侧链的存在是实现良好效力的基础。的升-Trp衍生物(20, PCM126) 是该系列中最有效的拮抗剂,可在低 μM 浓度下破坏 EphA2-ephrinA1 相互作用并阻断前列腺癌细胞中的 EphA2 磷酸化,因此比 LCA 更有效。化合物20是 EphA2 受体最有效的小分子拮抗剂之一。
    DOI:
    10.1021/jm301890k
点击查看最新优质反应信息

文献信息

  • Synthesis and Structure−Activity Relationships of 2-Substituted <scp>d</scp>-Tryptophan-Containing Peptidic Endothelin Receptor Antagonists:  Importance of the C-2 Substituent of the <scp>d</scp>-Tryptophan Residue for Endothelin A and B Receptor Subtype Selectivity
    作者:Takehiro Fukami、Takeru Yamakawa、Kenji Niiyama、Hisaki Kojima、Yuuka Amano、Fuyuko Kanda、Satoshi Ozaki、Takahiro Fukuroda、Masaki Ihara、Mitsuo Yano、Kiyofumi Ishikawa
    DOI:10.1021/jm9600914
    日期:1996.1.1
    Continuing studies on modifications of potent cyclic pentapeptide endothelin (ET) receptor antagonists, represented by BQ-123, and potent linear tripeptide derivative ET receptor antagonists, represented by BQ-788, are described herein. The introduction of D-tryptophan analogues with C-2 substituents in these peptidic ET antagonists resulted in potent ET receptor antagonists with various ETA/ETB subtype selectivity
    本文描述了以BQ-123为代表的有效环状五肽内皮素(ET)受体拮抗剂和以BQ-788为代表的有效线性三肽衍生物ET受体拮抗剂的修饰的持续研究。在这些肽类ET拮抗剂中引入具有C-2取代基的D-色氨酸类似物,可产生具有各种ETA / ETB亚型选择性的有效ET受体拮抗剂。在环状五肽和线性三肽系列中都发现带有2-卤代和2-甲基-D-色氨酸的联合ETA / ETB受体拮抗剂。相反,具有2-氰基-D-色氨酸的化合物是ETB受体选择性拮抗剂。D-色氨酸残基的C-2取代基似乎对于区分拮抗剂的ETA / ETB亚型选择性非常重要。
  • Visible-Light-Driven, Copper-Catalyzed Decarboxylative C(sp<sup>3</sup> )−H Alkylation of Glycine and Peptides
    作者:Chao Wang、Mengzhun Guo、Rupeng Qi、Qinyu Shang、Qiang Liu、Shan Wang、Long Zhao、Rui Wang、Zhaoqing Xu
    DOI:10.1002/anie.201809400
    日期:2018.11.26
    well‐developed and growing body of work in Cu catalysis, the potential of Cu to serve as a photocatalyst remains underexplored. Reported herein is the first example of visible‐light‐induced Cu‐catalyzed decarboxylative C(sp3)−H alkylation of glycine for preparing α‐alkylated unnatural α‐amino acids. It merits mentioning that the mild conditions and the good functional‐group tolerance allow the modification
    尽管铜催化方面的工作已经发展成熟并且在不断发展,但是铜作为光催化剂的潜力仍未得到开发。本文报道的是第一个可见光诱导的铜催化甘氨酸脱羧C(sp 3)-H烷基化制备甘氨酸α-烷基化非天然α-氨基酸的例子。值得一提的是,温和的条件和良好的官能团耐受性允许使用此方法对肽进行修饰。机理研究表明,该反应涉及自由基-自由基偶联途径。
  • Benzoxazepinones and their use as squalene synthase inhibitors
    申请人:——
    公开号:US20030078251A1
    公开(公告)日:2003-04-24
    There is disclosed a compound represented by the formula [I]: 1 wherein R 1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, —X 1 —X 2 —Ar—X 3 —X 4 —COOH (wherein X 1 and X 4 are a bond or alkylene group, X 2 and X 3 are a bond, —O—, —S—, Ar is divalent aromatic group etc.), R 2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R 3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.
    披露了一种由公式[I]表示的化合物: 1 其中R 1 是可选地取代的1-羧乙基,可选地取代的烷基亚磺酰基,可选地取代的(羧基环烷基)-烷基,—X 1 —X 2 —Ar—X 3 —X 4 —COOH(其中X 1 和X 4 是键或亚烷基,X 2 和X 3 是键,—O—,—S—,Ar是二价芳香族等),R 2 是可选地由酰氧基和/或羟基取代的烷基,R 3 是烷基,W是卤素原子等,或其盐。该化合物具有降低胆固醇活性和降低甘油三酯活性,用于预防或治疗高脂血症。
  • Inhibitors of protein isoprenyl transferases
    申请人:University of Pittsburgh
    公开号:US20020193596A1
    公开(公告)日:2002-12-19
    Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.
    具有以下公式的化合物或其药学上可接受的盐,其中R1为(a)氢,(b)较低的烷基,(c)烯基,(d)烷氧基,(e)硫代烷氧基,(f)卤素,(g)卤代烷基,(h)芳基-L2—,以及(i)杂环-L2—;R2从(a)中选择,(b) -C(O)NH-CH(R14)-C(O)OR15,(c)中选择,(d) -C(O)NH-CH(R14)-C(O)NHSO2R16,(e) -C(O)NH-CH(R14)-四唑基,(f) -C(O)NH-杂环,以及(g) -C(O)NH-CH(R14)-C(O)NR17R18;R3为杂环,芳基,取代或未取代的环烷基;R4为氢,较低烷基,卤代烷基,卤素,芳基,芳基烷基,杂环基,或(杂环)烷基;L1为空缺或从(a) -L4-N(R5)-L5-,(b) -L4-O-L5-,(c) -L4-S(O)n-L5-,(d) -L4-L6-C(W)-N(R5)-L5-,(e) -L4-L6-S(O)m-N(R5)-L5-,(f) -L4-N(R5)-C(W)-L7-L5-,(g) -L4-N(R5)-S(O)p-L7-L5-,(h)可选择取代的烷基,(i)可选择取代的烯基,以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。
  • Chiral Arylated Amines via C−N Coupling of Chiral Amines with Aryl Bromides Promoted by Light
    作者:Geyang Song、Liu Yang、Jing‐Sheng Li、Wei‐Jun Tang、Wei Zhang、Rui Cao、Chao Wang、Jianliang Xiao、Dong Xue
    DOI:10.1002/anie.202108587
    日期:2021.9.20
    molecular Ni catalysis driven by light, which enables stereoretentive C-N coupling of optically active amines, amino alcohols, and amino acid esters with aryl bromides, with no need for any external photosensitizer. The method is effective for a wide variety of coupling partners, including those bearing functional groups sensitive to bases and nucleophiles, thus providing a viable alternative to accessing
    Buchwald-Hartwig CN 偶联反应已在有机合成中得到广泛应用。在过去二十年左右的时间里,已经引入了许多改进的催化剂,现在可以很容易地使用各种胺和芳基亲电试剂。然而,缺乏可用于偶联各种手性胺和芳基卤而不会侵蚀过量对映体 ( ee) 的方案)。本文报道了一种基于光驱动的分子 Ni 催化的方法,该方法能够使旋光胺、氨基醇和氨基酸酯与芳基溴进行立体保留 CN 偶联,无需任何外部光敏剂。该方法对多种偶联伙伴有效,包括那些带有对碱和亲核试剂敏感的官能团的偶联伙伴,从而为获取合成重要的手性N-芳基胺、氨基醇和氨基酸酯提供了可行的替代方案。92 个例子证明了它的可行性,ee高达 99% 。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物